Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Tue, February 11, 3:31 PM
This Slide: #114 of 631 |
Slide #114. VistaGen Therapeutics, Inc. — Preferred Stock Offering
Company:
VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
Date announced:
12/17/2020
Shares Offered:
2,000,000
Date of Pricing:
12/18/2020
Price Per Share:
$21.16
Preferred Stock Offering Details:
VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the "Common Stock"), and its Series D convertible preferred stock (the "Series D Preferred Stock"). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 12/18- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the "Common Stock"), and 2,000,000 shares of its Series D convertible preferred stock ("Series D Preferred Stock") at a public offering price of $21.16 per share.
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. Co. is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain.
Open the VTGN Page at Preferred Stock Channel »
![]()
![]() |
![]() ![]() |
Open the VTGN Page at Preferred Stock Channel (in a new window) »

![]() ![]() Get Dividend Alerts ![]() Get SEC Filing Alerts ![]() ![]() |
![]() Strong Buy (4.00 out of 4) 79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com ![]() |

![]() ![]() |